<DOC>
	<DOCNO>NCT02657213</DOCNO>
	<brief_summary>The main objective evaluate efficacy sensor augment pump ( SAP ) therapy MiniMed 640G SmartGuard activation prevent hypoglycemia event comparison sensor augment pump ( SAP ) therapy Minimed 640G without SmartGuard activation type 1 diabetic adult increase risk hypoglycemia . The study show : - A reduction number severe hypoglycemia , few hypoglycemic event reduction time spend hypoglycemia six month group compare Baseline . - A complete prevention severe severe hypoglycemia pump group Minimed 640G + Enlite sensor SmartGuard activation</brief_summary>
	<brief_title>Study Insulin Pump Prevention Low Glucose Events Adults With Type 1 Diabetes Risk Severe Hypoglycemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 insulindependent diabetic patient Patients treat subcutaneous insulin pump least 2 episode severe hypoglycemia within 12 month study enrollment Affiliation french social security system equivalent People sign consent form Patient difficulty understand French language Patient raise use insulin pump , glucose sensor Patient visually impair Patient hard hearing Pregnant woman woman project pregnancy within 6 month Persons refer Articles L11215 L11218 CSP : pregnant woman , woman labor , breastfeed woman , person deprive liberty judicial administrative decision , person legal protection measure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes , Type 1</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin Infusion Systems</keyword>
</DOC>